Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00050687 · ClinicalTrials.gov registry record · Phase 1
Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various Refractory Malignancies
A Phase 1 study, sponsored by Titan Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
NCT00050687 is a Phase 1 study that was terminated before completion, run by Titan Pharmaceuticals.
The verdict
NCT00050687, a Phase 1 study, was terminated before completion, sponsored by Titan Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
Study Summary
This study will test the safety, tolerance, and efficacy of different doses of oral gallium maltolate. Patients will receive oral gallium maltolate twice daily for 28-consecutive days followed by 14 days off treatment. This dosing cycle will be repeated. Adverse effects will be assessed and the levels of gallium in serum will be measured. Any effect of the drug on the cancer and any improvement in cancer-related symptoms will also be measured.
Interventions
- DRUG Gallium maltolate
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-06 |
| Est. Completion | 2005-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00050687
The ClinicalTrials.gov registry entry for NCT00050687 describes a study currently listed as terminated, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Titan Pharmaceuticals, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Gallium maltolate is the first listed.
NCT00050687 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00050687 about?
NCT00050687 is a clinical study titled "Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various Refractory Malignancies". This study will test the safety, tolerance, and efficacy of different doses of oral gallium maltolate. Patients will receive oral gallium maltolate twice daily for 28-consecutive days followed by 14 days off treatment. This dosing cycle will be repeated. Adverse effects will be assessed and the leve...
What is the current status of trial NCT00050687?
This trial is currently terminated. It is a Phase 1 study. The study started on 2001-06. Estimated completion is 2005-03.
What interventions are being tested in trial NCT00050687?
The interventions under investigation include: Gallium maltolate (DRUG).
Who is sponsoring clinical trial NCT00050687?
This trial is sponsored by Titan Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.